zooplus AG

  • WKN: 511170
  • ISIN: DE0005111702
  • Land: Deutschland

Nachricht vom 18.10.2021 | 12:45

zooplus AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

zooplus AG
18.10.2021 / 12:45
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer
Name: zooplus AG
Street: Sonnenstraße 15
Postal code: 80331
City: München
Germany
Legal Entity Identifier (LEI): 549300VB13ZT2X88PU78

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
X Other reason:
voluntary group notification with triggered threshold on subsidiary level

3. Details of person subject to the notification obligation
Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
11 Oct 2021

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 3.20 % 1.56 % 4.76 % 7,149,178
Previous notification 4.43 % 0.20 % 4.62 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0005111702 0 229,093 0.00 % 3.20 %
Total 229,093 3.20 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
Right of recall over securities lending agreements at any time at any time 111,312 1.56 %
    Total 111,312 1.56 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
Retail Structured Product From 02.02.2067 to 29.06.2070 at any time Cash 3 0.00 %
      Total 3 0.000041962866 %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
Morgan Stanley % % %
Morgan Stanley Capital Management, LLC % % %
Morgan Stanley Domestic Holdings, Inc. % % %
Morgan Stanley & Co. LLC % % %
- % % %
Morgan Stanley % % %
Morgan Stanley International Holdings Inc. % % %
Morgan Stanley International Limited % % %
Morgan Stanley Investments (UK) % % %
Morgan Stanley & Co. International plc % % %
- % % %
Morgan Stanley % % %
Morgan Stanley Capital Management, LLC % % %
Morgan Stanley Domestic Holdings, Inc. % % %
Morgan Stanley & Co. LLC % % %
Prime Dealer Services Corp. % % %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
15 Oct 2021



18.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben

30. November 2021, 16:02

Aktueller Webcast

Adler Group S.A.

Nine-Month
Investor Call
Q3 2021

30. November 2021

Aktuelle Research-Studie

clearvise AG

Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy

30. November 2021